Skip to Primary Content
Skip to Footer
home
about
products & pipeline
Clinical Trials
Publications
newsroom
investors
Stock Information
Press Releases
Events & Presentations
SEC Filings
ESG
Financial Information
partners
careers
Afrezza.com
818.661.5000
careers
partners
investors
Stock Information
Press Releases
Events & Presentations
SEC Filings
ESG
Financial Information
newsroom
products & pipeline
Clinical Trials
Publications
about
News & Events
March 27, 2016
Improving Efficacy of Inhaled Technosphere Insulin (Afrezza) by Postmeal Dosing: In-silico Clinical Trial with the University of Virginia/Padova Type 1 Diabetes Simulator.
previous post
next post
×